These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 12784820)

  • 1. Primary PCI for ST-segment elevation myocardial infarction in a patient treated with subcutaneous enoxaparin utilizing point-of-care Enox test.
    Veerappan B; Latif F; Patibandla S; Hennebry T; Ghani M; Saucedo J; Schechter E; Sadanandan S
    J Invasive Cardiol; 2003 May; 15(5):4p following A16. PubMed ID: 12784820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subcutaneous enoxaparin with early invasive strategy in patients with acute coronary syndromes.
    Collet JP; Montalescot G; Golmard JL; Tanguy ML; Ankri A; Choussat R; Beygui F; Drobinski G; Vignolles N; Thomas D
    Am Heart J; 2004 Apr; 147(4):655-61. PubMed ID: 15077081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Percutaneous coronary intervention in patients receiving enoxaparin or unfractionated heparin after fibrinolytic therapy for ST-segment elevation myocardial infarction in the ExTRACT-TIMI 25 trial.
    Gibson CM; Murphy SA; Montalescot G; Morrow DA; Ardissino D; Cohen M; Gulba DC; Kracoff OH; Lewis BS; Roguin N; Antman EM; Braunwald E;
    J Am Coll Cardiol; 2007 Jun; 49(23):2238-46. PubMed ID: 17560287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enoxaparin and percutaneous coronary intervention: a Canadian perspective.
    Fitchett D; Welsh R; Langer A; Goodman S
    Can J Cardiol; 2005 May; 21(6):501-7. PubMed ID: 15917879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The combination of enoxaparin, glycoprotein IIb/IIIa inhibitors and an early invasive approach among acute coronary syndrome patients.
    Lee DS; Bhatt DL; Moliterno DJ; Peacock WF; Ellis SG; Topol EJ
    J Invasive Cardiol; 2004 Feb; 16(2):46-51. PubMed ID: 14760188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of intravenous/subcutaneous Enoxaparin in patients with acute coronary syndrome undergoing percutaneous coronary interventions.
    Aslam MS; Sundberg S; Sabri MN; Cooke D; Lakier JB
    Catheter Cardiovasc Interv; 2002 Oct; 57(2):187-90. PubMed ID: 12357518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized comparative study of using enoxaparin instead of unfractionated heparin in the intervention treatment of coronary heart disease.
    Chen JL; Chen J; Qiao SB; Guo YL; Wu YJ; Dai J; Yuan JQ; Qin XW; Yang YJ; Gao RL
    Chin Med J (Engl); 2006 Mar; 119(5):355-9. PubMed ID: 16542576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are activated clotting times helpful in the management of anticoagulation with subcutaneous low-molecular-weight heparin?
    Henry TD; Satran D; Knox LL; Iacarella CL; Laxson DD; Antman EM
    Am Heart J; 2001 Oct; 142(4):590-3. PubMed ID: 11579347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploring the role of enoxaparin in the management of high-risk patients with non-ST-elevation acute coronary syndromes: the SYNERGY trial.
    Mahaffey KW; Ferguson JJ
    Am Heart J; 2005 Apr; 149(4 Suppl):S81-90. PubMed ID: 16124952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial.
    White HD; Kleiman NS; Mahaffey KW; Lokhnygina Y; Pieper KS; Chiswell K; Cohen M; Harrington RA; Chew DP; Petersen JL; Berdan LG; Aylward PE; Nessel CC; Ferguson JJ; Califf RM
    Am Heart J; 2006 Dec; 152(6):1042-50. PubMed ID: 17161049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syndromes: an individual patient-level combined analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) randomized trials.
    Mehta SR; Boden WE; Eikelboom JW; Flather M; Steg PG; Avezum A; Afzal R; Piegas LS; Faxon DP; Widimsky P; Budaj A; Chrolavicius S; Rupprecht HJ; Jolly S; Granger CB; Fox KA; Bassand JP; Yusuf S;
    Circulation; 2008 Nov; 118(20):2038-46. PubMed ID: 18955665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can enoxaparin safely replace unfractionated heparin during coronary intervention in acute coronary syndromes?
    Wolak A; Ayzenberg Y; Cafri C; Gilutz H; Ilia R; Zahger D
    Int J Cardiol; 2004 Aug; 96(2):151-5. PubMed ID: 15262028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial.
    Mehta SR; Granger CB; Eikelboom JW; Bassand JP; Wallentin L; Faxon DP; Peters RJ; Budaj A; Afzal R; Chrolavicius S; Fox KA; Yusuf S
    J Am Coll Cardiol; 2007 Oct; 50(18):1742-51. PubMed ID: 17964037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of anticoagulants in ST-elevation myocardial infarction patients undergoing percutaneous coronary intervention: a potential role for enoxaparin.
    Christy GW
    J Invasive Cardiol; 2008 Nov; 20(11):615-21. PubMed ID: 18987403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enoxaparin in patients with primary percutaneous coronary intervention for acute ST segment elevation myocardial infarction.
    Schwarz AK; Zeymer U
    Future Cardiol; 2009 Jan; 5(1):43-9. PubMed ID: 19371202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Avoiding intelligence failures in the cardiac catheterization laboratory: Strategies for the safe and rational use of dalteparin or enoxaparin during percutaneous coronary intervention.
    Marmur JD; Bullock-Palmer RP; Poludasu S; Cavusoglu E
    J Invasive Cardiol; 2009 Dec; 21(12):653-64. PubMed ID: 19966370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial.
    Ferguson JJ; Califf RM; Antman EM; Cohen M; Grines CL; Goodman S; Kereiakes DJ; Langer A; Mahaffey KW; Nessel CC; Armstrong PW; Avezum A; Aylward P; Becker RC; Biasucci L; Borzak S; Col J; Frey MJ; Fry E; Gulba DC; Guneri S; Gurfinkel E; Harrington R; Hochman JS; Kleiman NS; Leon MB; Lopez-Sendon JL; Pepine CJ; Ruzyllo W; Steinhubl SR; Teirstein PS; Toro-Figueroa L; White H;
    JAMA; 2004 Jul; 292(1):45-54. PubMed ID: 15238590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin.
    Montalescot G; Collet JP; Tanguy ML; Ankri A; Payot L; Dumaine R; Choussat R; Beygui F; Gallois V; Thomas D
    Circulation; 2004 Jul; 110(4):392-8. PubMed ID: 15249498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emergency percutaneous coronary intervention (PCI) for the care of patients with ST-elevation myocardial infarction (STEMI).
    Morrison DA; Berman M; El-Amin O; McLaughlin RT; Bates ER
    Minerva Cardioangiol; 2007 Oct; 55(5):593-623. PubMed ID: 17912165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical benefit of enoxaparin in patients with high-risk acute coronary syndromes without ST elevations in clinical practice.
    Zeymer U; Gitt A; Jünger C; Koeth O; Zahn R; Wienbergen H; Gottwik M; Senges J;
    Am J Cardiol; 2006 Jul; 98(1):19-22. PubMed ID: 16784913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.